

Intraindividual Variation in Plasma 25-Hydroxyvitamin D Measures 5 Years Apart among Postmenopausal Women

Jennifer E. Meng¹, Kathleen M. Hovey¹, Jean Wactawski-Wende¹, Christopher A. Andrews², Michael J. LaMonte¹, Ronald L. Horst⁴, Robert J. Genco³, and Amy E. Millen¹

Abstract

Background: Current literature examining associations between vitamin D and chronic disease generally use a single assessment of 25-hydroxyvitamin D [25(OH)D], assuming the 25(OH)D concentration of an individual is consistent over time.

Methods: We investigated the intraindividual variability between two measures of plasma 25(OH)D concentrations collected approximately five years apart (1997–2000 to 2002–2005) in 672 postmenopausal women participating in the Women's Health Initiative. Plasma 25(OH)D was assessed using the DiaSorin LIAISON[®] chemiluminescence immunoassay. The within-pair coefficient of variation (CV) was 4.9% using blinded quality control samples. Mean and SDs of 25(OH)D at the two time points were compared using a paired *t* test. An intraindividual CV and intraclass correlation coefficient (ICC) were used to assess intraindividual variability. A Spearman correlation coefficient (*r*) assessed the strength of the association between the two measures, and concordance in vitamin D status at two time points was compared.

Results: Mean 25(OH)D concentrations (nmol/L) significantly increased over time from 60.0 (SD = 22.2) to 67.8 (SD = 22.2; *P* < 0.05). The CV was 24.6%, the ICC [95% confidence interval (CI)] was 0.59 (0.54–0.64), and the Spearman *r* was 0.61 (95% CI = 0.56–0.66). Greater concordance over five years was observed in participants with sufficient compared with deficient or inadequate baseline 25(OH)D concentrations (weighted kappa = 0.39). Reliability measures were moderately influenced by season of blood draw and vitamin D supplement use.

Conclusion: There is moderate intraindividual variation in 25(OH)D concentrations over approximately five years.

Impact: These data support the use of a one-time measure of blood 25(OH)D in prospective studies with ≤ five years of follow-up. *Cancer Epidemiol Biomarkers Prev*; 21(6); 916–24. ©2012 AACR.

Introduction

Vitamin D may play a role in the pathophysiology of multiple chronic diseases states. The recent Institute of Medicine's (IOM) report on Dietary Reference Intakes for calcium and vitamin D concluded that the current data are inconclusive with regard to a causal role of vitamin D in disease states other than bone health (e.g., cancer, cardiovascular disease, and autoimmune disease; ref. 1). In the coming years, additional research will add to the literature on the role of vitamin D status in relation to various health outcomes. Thus, understanding variability of

vitamin D status over time for use in clinical and population research is needed.

Individual vitamin D status is best assessed with blood concentrations of 25-hydroxyvitamin D [25(OH)D], which reflects exposure from all vitamin D sources (diet, supplements, and sunlight) and reflects vitamin D status over an approximate preceding 3-week period (2, 3). Of the current literature assessing associations between blood measures of vitamin D and disease, most studies have used a single measure of 25(OH)D and have adjusted for date of blood draw during data analysis. These studies assume that individual vitamin D measurements are consistent over time. If this assumption is not true, then a single blood measure of 25(OH)D may have minimal relation to health beyond its short-term physiologic effects. More research is needed to better understand the intraindividual variation in blood concentrations of 25(OH)D over periods of years. This information will aid in interpreting the scientific literature and will inform on the reliability of using one measure of 25(OH)D to reflect a longer time period of exposure in studies of vitamin D status and chronic disease risk.

Authors' Affiliations: Departments of ¹Social and Preventive Medicine and ²Biostatistics, School of Public Health and Health Professions, ³Department of Oral Biology, School of Dental Medicine, University at Buffalo, The State University of New York, Buffalo, New York; and ⁴Heartland Assays, Inc., Ames, Iowa

Corresponding Author: Amy E. Millen, Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, The State University of New York, 270 Farber Hall, Buffalo, NY 14214-8001. Phone: 716-829-5377; Fax: 716-829-2979; E-mail: aemillen@buffalo.edu.

doi: 10.1158/1055-9965.EPI-12-0026

©2012 American Association for Cancer Research.

To date, 5 studies (4–8) have investigated the intraindividual variation in blood 25(OH)D concentrations over a period of 3 to 14 years, but 4 of 5 had small sample sizes ($n < 187$). In the largest study, Jorde and colleagues (7), examined the intraindividual variation in a sample of 2,688 men and women, of which only 759 participants had blood samples drawn during the same time of year. Together these studies have found that 25(OH)D levels vary moderately within individuals over time with coefficients of variation (CV) ranging from 14.9% to 18.4%. Additional studies with larger sample sizes are needed to confirm these findings and explore subgroups for which variation may be lowest.

Data from the Buffalo Osteoporosis and Periodontal Disease Study, an ancillary study of the Women Health Initiative (WHI) Observation Study, provides a unique opportunity to quantify intraindividual variation in plasma 25(OH)D concentrations among a well-characterized sample of 672 postmenopausal women with blood measures taken at 2 time points, approximately 5 years apart (1997–2000 to 2002–2005). The same vitamin D assay was used to measure 25(OH)D concentrations in all plasma samples from both time points over a consecutive 4-month period. We hypothesized that there would be minimal to moderate intraindividual variability of 25(OH)D concentrations between the 2 measurements. This study will aid in better understanding how measures of vitamin D status vary over time among postmenopausal women. Specifically, this study will help interpret current and future WHI studies showing associations between vitamin D status and disease outcomes.

Methods

Study sample

The WHI is a large multicenter study of postmenopausal women, including more than 161,000 women aged 50 to 79 years at the time of enrollment from 1993 to 1998 (9, 10). The WHI includes a set of clinical trials and a prospective observational study. The participants included in this analysis are women from the WHI Observational Study who participated in the ancillary Osteoporosis and Periodontal Disease (OsteoPerio) Study, conducted at the University at Buffalo clinical center (previously described; ref. 11) and had available data and stored samples for studying relationships of 25(OH)D concentrations and periodontal disease. All WHI participants in the Observational Study are mutually exclusive from WHI participants in the WHI Clinical Trials (e.g., the Calcium and Vitamin D Clinical Trial).

There were 2,249 women who participated in the WHI Observational Study at the Buffalo center. The details of the OsteoPerio Study eligibility, recruitment, and follow-up study have been previously described (11, 12). In brief, all women were invited to participate in the OsteoPerio Study at the WHI year 3 clinic visit (1997–2000). Of these, 549 women were unable to be reached, not interested, deceased, canceled after accepting, or were temporarily ineligible, and 338 women did not meet the specified

inclusion criteria. Among the remaining 1,362 individuals, 5 did not complete or return study questionnaires and 16 did not have adequate oral x-rays needed for determination of alveolar crestal height. This left a sample of 1,341 women with available data on periodontal disease. There were 934 women who had plasma samples available for 25(OH)D assessment at OsteoPerio baseline (1997–2000). There were 231 women who did not return for follow-up (36 were deceased, 76 were ineligible, 112 were not interested, and 7 were lost or withdrew from WHI) and 30 women did participate in follow-up but did not provide a blood sample. Therefore, 673 women also had available plasma drawn for 25(OH)D assessment at the 5-year follow-up study (2002–2005). The Institutional Review Board at the University at Buffalo approved all protocols, and consent forms and participants provided written informed consent for all study activities in the WHI and ancillary OsteoPerio Study.

Data collection

At the baseline OsteoPerio visit, participants completed a standardized set of self-administered questionnaires pertaining to personal and family health history and lifestyle habits and had an extensive clinic examination following standardized protocols (11, 12). The physical examination components included measured height and weight and a fasting blood draw. Questionnaire information included participation in recreational physical activity (13) and intake of vitamin D from foods assessed from a food frequency questionnaires (14). Participants were asked to bring in current medications and supplements they were taking and reported their dose and frequency of use. The same clinic examinations, questionnaires, and medication and supplement use inventory were repeated at the OsteoPerio 5-year follow-up visit (2002–2005).

Assessment of 25-hydroxyvitamin D status

At both OsteoPerio baseline and follow-up, fasting blood samples were collected from participants by a trained phlebotomist and processed using a standardized protocol. The average time between blood sample at baseline and follow-up was 5.1 years. Effort was made in the OsteoPerio study to bring women in for the baseline and follow-up study visits at the same time of year, as near as feasible to their baseline calendar date, because previous data has shown that bone tissue mass varies by season (15).

Plasma samples were stored in 0.5-mL straws in liquid nitrogen at -196°C until the time of 25(OH)D measurements when they were removed from liquid nitrogen, put in a -80°C freezer, thawed, and aliquoted under standard protocol into cryovials. Samples were refrozen and shipped on dry ice to the Heartland Assays, Inc. laboratory where they were thawed and assayed. All assays were run over a consecutive 4-month period. Assays for plasma drawn at baseline were run first followed by assays for plasma drawn at follow-up. Duplicate participant samples were run in separate batches.

Plasma 25(OH)D concentrations were measured by competitive chemiluminescence immunoassay using the DiaSorin LIAISON® 25(OH)D assay. The within-pair CV was 4.9% using the investigators' blinded duplicate quality control samples that were nested in each batch. One woman was excluded from the analysis because her baseline 25(OH)D concentration was extremely high (530 nmol/L) reportedly due to taking a high level of vitamin D supplements for calcium deficiency leaving 672 participants for the current analysis. The majority (84.2%) of participants had bloods drawn at follow-up within 90 days from their baseline month of blood draw due to the study's efforts to bring women in at follow-up at a similar time of year.

Statistical analysis

Basic descriptive characteristics of this study sample were described at OsteoPerio baseline including age, race, education, smoking status, hormone therapy use, body mass index (BMI), and physical activity levels. Plasma concentrations of 25(OH)D, season of blood draw (January–March, April–June, July–September, October–December), and intake of vitamin D from foods and supplements (IU/d) at baseline and follow-up were compared with described changes in vitamin D status and intake over time. Paired *t* tests or Bowker test of symmetry, where applicable, were conducted to examine difference between baseline and follow-up concentrations of plasma 25(OH)D and vitamin D intake.

Spearman correlation coefficients (*r*) were calculated to determine the strength of the relationship between baseline and follow-up 25(OH)D concentrations. In addition, an intraclass correlation coefficient (ICC) and an intraindividual coefficient of variation (CV) were estimated to assess intraindividual variation in plasma 25(OH)D concentrations between the 2 time points. The ICC was estimated using $ICC = V_b/V_t$, in which V_b = variance between individuals and V_t = total variance (16). The higher the ICC, the greater the proportion of total variation in 25(OH)D concentrations between time points owed to differences between individuals, rather than intraindividual variability or measurement errors. The intraindividual CV was computed, using the root mean square approach as described by Bland (17).

In exploratory analyses, the influence of season of blood draw and supplement use patterns over time on the reliability of 2 measures of 25(OH)D 5 years apart were examined. The above analyses were repeated among participants whose bloods were drawn (i) in the same season [winter (January–March), spring (April–June), summer (July–September), and fall (October–December)] at baseline and follow-up ($n = 444$), (ii) in different seasons at baseline and follow-up (using the 4 noted seasons; $n = 228$), and (iii) opposite times of year (e.g., January–March compared with July–September) between baseline and follow-up ($n = 49$ of the 228).

Similarly, analyses were repeated for participants who reported (i) no use of vitamin D supplements at baseline

and follow-up ($n = 54$), (ii) vitamin D supplement use at baseline but not follow-up ($n = 18$), (iii) no vitamin D supplement use at baseline but vitamin D supplement use at follow-up ($n = 133$), and (iv) vitamin D supplement use at both time points ($n = 463$). Participants were further collapsed into 2 groups representing women whose use of vitamin D supplements did not change over time ($n = 517$) and women whose vitamin D supplement use did change over time ($n = 151$), and analyses were repeated in these 2 groups.

Linear regression was conducted to understand the general magnitude of the relationship between 25(OH)D status at the 2 time points. Effect modification of the linear regression analysis of follow-up 25(OH)D concentrations on baseline 25(OH)D concentrations by season of blood draw (same season or different season of blood draw at both time points), as well as by supplement use (consistent use over time or change in use over time), were conducted. A *P* value of < 0.05 was considered statistically significant.

Finally, deciles were created for baseline and follow-up 25(OH)D concentrations independently. Participants were also categorized at baseline and follow-up according to clinical cutpoints of vitamin D status defined by the recent IOM report: persons at risk for deficiency (<30 nmol/L), persons at risk for inadequacy (≥ 30 to <50 nmol/L; ref. 1). Two categories were investigated as being adequate, ≥ 50 nmol/L to <75 nmol/L and ≥ 75 nmol/L. The cross-tabulation of deciles and clinically defined cutpoints assessed at baseline and follow-up was examined to determine how the placement of an individual in a category changed over time. Weighted kappa statistics using the Cicchetti–Allison methods for weights were calculated using both decile and clinical categories (18).

Data analysis and figures were completed using SAS version 9.2.

Results

Table 1 shows descriptive characteristics of our study sample at baseline. The mean age at baseline was 65.7 years and most of the participants were Caucasian and highly educated. The majority of participants were never-smokers (55.1%) and current users of hormone therapy (51.2%). The mean BMI at baseline was 26.6 kilograms/meter² (kg/m²) and mean physical activity levels at baseline were 14.5 metabolic equivalents task (MET) h/wk.

Table 2 shows the mean 25(OH)D concentrations, the percentage of individuals classified into clinical vitamin D levels, and the mean vitamin D intake from food and supplements at baseline and follow-up. The mean 25(OH)D concentration significantly increased between baseline (60.0 nmol/L) and follow-up (67.8 nmol/L). At follow-up as compared with baseline, there were fewer participants classified as at risk for deficiency or inadequacy (19.8% vs. 32%). The mean vitamin D intake from foods, the percentage of any vitamin D supplement use, and the

Table 1. Descriptive characteristics of participants with plasma 25(OH)D concentrations at Osteoporosis and Periodontal Disease (OsteoPerio) Study baseline (1997–2000) and follow-up (2002–2005; $n = 672$)

Age at visit (y), mean \pm SD	65.7 \pm 6.7
Race/Ethnicity, n (%)	
Caucasian	663 (98.7)
African American,	4 (0.6)
American Indian/Alaskan Native	4 (0.6)
Asian/Pacific Islander	1 (0.2)
Education level, n (%)	
Some high school	11 (1.6)
High school diploma/GED ^a	121 (18.0)
School after high school	211 (31.4)
College degree or higher	321 (47.8)
N Missing	8 (1.2)
Smoking status, n (%)	
Current	14 (2.1)
Former	288 (42.9)
Never	370 (55.1)
Hormone therapy use, n (% any use) ^b	344 (51.2)
BMI (kg/m ²) ^c , mean \pm SD	26.6 \pm 4.9
Physical activity (MET ^d -h/wk), mean \pm SD	14.5 \pm 14.4

^aGeneral Equivalency Diploma.

^bCurrent use of estrogen and/or progestin.

^cKilograms/meters².

^dMetabolic equivalents task.

percentage of high-dose vitamin D supplements use increased from baseline to follow-up. As a result, the mean intake of vitamin D from foods and supplements combined also increased from 536.9 to 775.7 IU/d.

The distribution of changes in 25(OH)D (follow-up minus baseline) concentrations was examined. There were 42.4%, 69.9%, and 86.6% participants whose 25(OH)D concentrations remained within a 10, 20, and 30 nmol/L range, respectively, between the 2 time points. Among participants whose blood was drawn in the same season at both time points, there were 44.4%, 71.9%, and 87.8% participants whose 25(OH)D concentrations remained within a 10, 20, and 30 nmol/L range, respectively.

In the overall sample, the Spearman r and 95% confidence interval (CI) was $r = 0.61$ (95% CI: 0.56–0.66) and the intraindividual CV was 24.6% (Table 3). The ICC was modest at 0.59 (95% CI: 0.54–0.64). Individuals who had their blood draw in the same compared with different seasons at baseline and follow-up had slightly stronger reliability measures, as expected (Table 3). Among participants whose bloods were drawn in the same season, reliability measures were strongest among women whose bloods were drawn in summer and fall at both time points compared with participants whose bloods were drawn in

Table 2. Plasma 25(OH)D concentrations, season of blood draw, and vitamin D intake from foods and supplements at Osteoporosis and Periodontal Disease (OsteoPerio) Study baseline (1997–2000) and follow-up (2002–2005) among women with plasma 25(OH)D concentrations at both time points ($n = 672$)

	Baseline	Follow-up
Plasma 25(OH)D concentrations (nmol/L), mean \pm SD	60.0 \pm 22.2	67.8 \pm 22.2 ^a
Plasma 25(OH)D concentrations (nmol/L), range	5.9–147.2	13.0–185.8
Clinical 25(OH)D levels, n (%)		
At risk for deficiency (<30 nmol/L)	58 (8.6)	22 (3.7) ^a
At risk for inadequacy (\geq 30–<50 nmol/L)	157 (23.4)	108 (16.1)
Adequate (\geq 50–<75 nmol/L)	305 (45.4)	317 (47.2)
Adequate (\geq 75 nmol/L)	152 (22.6)	225 (33.5)
Season of blood draw, n (%)		
January–March	143 (21.3)	160 (23.8) ^a
April–June	163 (24.3)	180 (26.8)
July–September	182 (27.1)	168 (25.0)
October–December	184 (27.4)	164 (24.4)
Vitamin D intake from foods (IU/d), mean \pm SD	200.5 \pm 130.3	246.4 \pm 245.2 ^a
Vitamin D supplement usage, n (%)		
None	189 (28.1)	72 (10.7) ^a
\leq 400 IU/d	324 (48.2)	237 (35.3)
>400 IU/d	159 (23.7)	359 (53.4)
N Missing	0	4 (0.6)
Total vitamin D intake from foods and supplements (IU/d), mean \pm SD	536.9 \pm 319.7	775.7 \pm 439.1 ^a

^a P value less than 0.05 for paired t test when comparing means of continuous variables or Bowker test of symmetry when comparing proportions of categorical variables at baseline versus follow-up.

winter and spring. Spearman correlations and ICCs were larger for participants who reported no vitamin D supplement use at both time points and for participants who reported use only at baseline. The largest CV, indicating the greatest intraindividual variation, was 33.7% among participants who reported use at follow-up but not baseline. When the data was combined to compare participants who did and did not change their vitamin D supplement use over time, the reliability measures were stronger in those with stable supplementation use over time, as expected.

Table 3. Spearman correlation coefficients (*r*) and 95% CIs, intraindividual CV and ICC, and 95% CIs are presented for repeat measures of plasma 25(OH)D at baseline (1997–2000) and follow-up (2002–2005) among postmenopausal women from the Osteoporosis and Periodontal Disease (OsteoPerio) Study (*n* = 672) with and without stratification by season of blood draw and supplement use patterns

Sample	N	Spearman <i>r</i> (95% CI)	CV	ICC (95% CI)
All participants	672	0.61 (0.56–0.66)	24.6%	0.59 (0.54–0.64)
Same season ^a at baseline and follow-up	444	0.68 (0.63–0.73)	23.8%	0.64 (0.58–0.69)
Same season: Winter at baseline and follow-up	98	0.59 (0.44–0.71)	27.7%	0.60 (0.45–0.71)
Same season: Spring at baseline and follow-up	116	0.66 (0.54–0.75)	26.5%	0.62 (0.50–0.72)
Same season: Summer at baseline and follow-up	122	0.75 (0.66–0.82)	19.3%	0.63 (0.51–0.72)
Same season: Fall at baseline and follow-up	108	0.68 (0.56–0.77)	21.2%	0.67 (0.56–0.77)
Different seasons at baseline and follow-up	228	0.49 (0.38–0.58)	26.0%	0.48 (0.37–0.57)
Six months apart at baseline and follow-up	49	0.58 (0.35–0.74)	30.1%	0.59 (0.38–0.74)
No vitamin D supplement use ^b at baseline or follow-up	54	0.72 (0.56–0.73)	25.5%	0.65 (0.47–0.78)
Vitamin D supplement use at baseline but not follow-up	18	0.72 (0.36–0.88)	21.8%	0.78 (0.52–0.91)
Vitamin D supplement use at follow-up but not baseline	133	0.57 (0.45–0.68)	33.7%	0.48 (0.34–0.60)
Vitamin D supplement use at baseline and follow-up	463	0.59 (0.52–0.64)	21.3%	0.55 (0.49–0.61)
No change ^c in vitamin D supplement use between baseline and follow-up	517	0.62 (0.56–0.67)	21.8%	0.60 (0.55–0.66)
Vitamin D supplement use changed between baseline and follow-up	151	0.57 (0.45–0.67)	32.5%	0.51 (0.39–0.62)

^aSeasons are defined by the following 4 seasons: winter (January–March), spring (April–June), summer (July–September), and fall (October–December).

^bFour participants (2 users, 2 were nonusers) who reported vitamin D supplements use at baseline and are missing follow-up data are excluded. Use of vitamin D supplements is defined as any use of a vitamin D supplement.

^cChange in vitamin D supplement use is defined as a person who reported using any amount of vitamin D supplements at baseline and reported using no vitamin D supplements at follow-up and vice versa.

Figures 1–3 are scatter plots comparing baseline and follow-up concentrations of 25(OH)D. The depicted regression lines of 25(OH)D concentrations at follow-up regressed on 25(OH)D concentrations at baseline describe the magnitude of the relationship among participants whose bloods were drawn in similar (*n* = 444) compared with different (*n* = 228) seasons at both time points (Fig. 1), among participants whose bloods were drawn in similar seasons (*n* = 444) compared with opposite times of year at baseline and follow-up (*n* = 49; Fig. 2), and among participants who had similar (*n* = 517) and different (*n* = 151) vitamin D supplement use patterns at baseline and follow-up (Fig. 3). In Fig. 1 the regression lines are slightly different and the interaction between baseline 25(OH)D concentrations and season of blood draw (similar or different at both time points) was borderline statistically significant at *P* = 0.059. In Fig. 2, the regression lines are more similar to each other than depicted in Fig. 1, and the interaction between baseline 25(OH)D concentrations and season of blood draw was *P* = 0.60. In Fig. 3 the regression lines for participants with consistent and inconsistent supplement use over time were also similar to each other, and the interaction between baseline 25(OH)D concentrations and consistent supplement use over time (yes, no) was *P* = 0.16.

Weighted kappas were calculated comparing agreement between deciles and clinical vitamin D status at each time point. The weighted kappa was 0.42 (95% CI:

0.38–0.47) and 0.39 (95% CI: 0.34–0.44) using deciles and clinical vitamin D status, respectively. Among women with bloods drawn in the same season of blood draw (fall, winter, summer, or spring), the weighted kappas were 0.48 (95% CI: 0.43–0.54) for deciles and 0.42 (95% CI: 0.36–0.49) for clinical vitamin D status. Table 4 shows the concordance of classification using clinical categories for plasma 25(OH)D concentrations at baseline and at follow-up. There was greater concordance among those who were adequate at baseline and less concordance among those at risk for deficiency or insufficiency.

Discussion

In this study, we evaluated intraindividual variability of plasma 25(OH)D concentrations measured approximately 5 years apart in a group of 672 postmenopausal women. The mean 25(OH)D concentration increased (60.0–67.8 nmol/L) and the percent of women classified as either at risk for deficiency or inadequacy (<50 nmol/L) decreased (32%–19.8%) over time. Comparing 25(OH)D concentrations at baseline and follow-up, we observed a moderate ICC of 0.59 (95% CI: 0.54–0.64), an intraindividual CV of 24.6%, and a moderate Spearman *r* of 0.61 (95% CI = 0.56–0.66). The weighted kappa comparing the same clinical status cutpoints for vitamin D status at baseline and follow-up was fair at 0.39 (95% CI: 0.34–0.44). Together, these data suggest that there is moderate intraindividual variability of 25(OH)D concentrations over a 5-year




Figure 1. Scatter plot of plasma 25-hydroxyvitamin D [25(OH)D] concentrations assessed at follow-up (2002–2005) versus baseline (1997–2000) among participants in the Osteoporosis and Periodontal Disease (OsteoPerio) Study ($n = 672$) with least squares regression lines representing participants with bloods drawn in the same ($n = 444$) and different ($n = 228$) seasons at baseline and follow-up. Note: Solid regression line and circles (O) represents women with bloods drawn at baseline and follow-up in the same season. Dashed regression line and plus signs (+) represents women with bloods drawn in different seasons at baseline and follow-up. Seasons are defined by the following 4 seasons: winter (January–March), spring (April–June), summer (July–September), and fall (October–December).

period. Overall, these data support that a one-time assessment of plasma 25(OH)D adequately reflects vitamin D status over a 5-year period in postmenopausal women.

Reliability measures were also examined in participants with similar and different seasons of blood draw at baseline and follow-up. The reliability of repeat 25(OH)D measures in different seasons at baseline and follow-up were comparable, although slightly weaker, to the reliability of repeat measures of 25(OH)D when blood was drawn in the same season at both time points. The correlation coefficients observed in our study between repeat 25(OH)D measures in different seasons ($r = 0.49$) and opposite seasons ($r = 0.58$) were slightly higher than the correlation coefficient observed in a previous study ($r = 0.462$; ref. 19) that measured 25(OH)D concentrations in 121 Japanese women (aged 45–81 years) in both summer and winter months approximately 1.5 years apart. Other previously noted studies (4–8) on the variation in blood measures of 25(OH)D over time did not present data comparing the variation in blood measures drawn in different seasons.

The reliability of repeat 25(OH)D measures among participants with different supplementation practices over time was also compared. Overall, reliability measures were greater among participants with stable supplementation patterns over time compared with those




Figure 2. Scatter plot of plasma 25-hydroxyvitamin D [25(OH)D] concentrations assessed at follow-up (2002–2005) versus baseline (1997–2000) among participants in the Osteoporosis and Periodontal Disease (OsteoPerio) Study ($n = 672$) with least squares regression lines representing participants with bloods drawn in the same ($n = 444$) season and at opposite times of year ($n = 49$) at baseline and follow-up. Note: Solid regression line and circles (O) represents women with bloods drawn at baseline and follow-up in the same season. Dashed regression line and plus signs (+) represents women with bloods drawn at opposite times of year at baseline and follow-up. Seasons are defined by the following 4 seasons: winter (January–March), spring (April–June), summer (July–September), and fall (October–December). There were 444 women with bloods drawn at baseline and follow-up in the same season and 49 women with bloods drawn at baseline and follow-up at opposite times of year (January–March compared with July–September or April–June compared with October–December).

whose supplementation patterns changed over time. We did observe strong reliability measures among the 18 participants who reported using vitamin D supplements at baseline but not follow-up, but this subset had a relatively small sample size. Although we did not observe tremendous difference in 5-year variation in serum vitamin D concentrations within strata of seasonal and supplemental vitamin D use, there seems to be some. Future studies should include collection of information on seasonal and supplemental vitamin D use to further examine the potential modifying effect these factors could have on etiologic associations between serum vitamin D exposures assessed at a single time point and future disease risk.

This is the second largest study to our knowledge that has assessed intraindividual variability in 25(OH)D concentrations. Our results support findings from previous work (4–6, 8), which concluded that vitamin D concentrations are reliable over extended periods of time (e.g., approximately 5 years). We observed a Spearman r of 0.68 between 25(OH)D concentrations taken 5-year apart in the same season among 444 participants. This is higher




Figure 3. Scatter plot of plasma 25-hydroxyvitamin D [25(OH)D] concentrations assessed at follow-up (2002–2005) versus baseline (1997–2000) among participants in the Osteoporosis and Periodontal Disease (OsteoPerio) Study ($n = 672$) with least squares regression lines representing participants with similar ($n = 517$) and different ($n = 151$) self-reported vitamin D supplement use at baseline and follow-up. Note: Solid regression line and circles (O) represents women with similar self-reported vitamin D supplement use at baseline and follow-up. Dashed regression line and plus signs (+) represents women with different self-reported vitamin D supplement use at baseline and follow-up. Similar self-reported vitamin D supplement use included women who reported use at both baseline and follow-up or no use at both time points. Different self-reported vitamin D supplement use included women who reported use at baseline but no use at follow-up or no use at baseline and use at follow-up.

than the Spearman correlation ($r = 0.53$) between 2 same-season measures of plasma 25(OH)D separated by 5 years reported by Hoffman and colleagues (6) in 29 men and women (55–70 years). Jorde and colleagues (7) also reported a similar correlation (Pearson $r = 0.52$) between

2 measures of plasma 25(OH)D concentrations in 759 Norwegian men and women (50–74 years) with measures assessed at the same time of the year 14 years apart.

We observed an intraindividual CV of 24.6% that was slightly higher than what has been presented previously in the literature. Renjmark and colleagues (5) reported an intraindividual CV of 16% for repeat measures over 4 years in 187 peri- and postmenopausal women. Kotsopoulos and colleagues (8) reported an intraindividual CV of 18.4% with bloods drawn 3 times over a 3-year period. Similarly, a CV of 14.9% was reported in the earlier mentioned study by Hoffman and colleagues (6). We also observed a slightly lower ICC (0.59) than that reported by Hoffman and colleagues (6) of 0.71, and Kotsopoulos and colleagues (8) of 0.72, but the ICC in our study increased to 0.64 when our sample was limited to women with blood draws in the same season.

In our study, we found that 42.4% of the sample had a change in 25(OH)D concentrations of less than 10 nmol/L over 5 years. Similarly, Jorde and colleagues (7) observed that 45.8% of their participants also had a change in 25(OH)D plasma measurements of less than 10 nmol/L over 14 years. Therefore, over a 5- to 14-year period it seems that approximately 40% of individuals will have minimal (<10 nmol/L) changes in their 25(OH)D concentrations.

We observed an increase in mean 25(OH)D concentrations from baseline to follow-up from 60.0 to 67.8 nmol/L, even though one might expect a decrease in concentrations with increasing age. This suggests that, in some women, true change in 25(OH)D concentrations is occurring over time. However, the agreement measures still suggest that this change moderately influences ranking of women in the cohort with respect to 25(OH)D concentrations. The observed mean increase in 25(OH)D concentrations over time could be explained, in part, by the observed increases in vitamin D intake from foods and supplements from baseline to follow-up. This change could also be explained by an interaction between increased vitamin D intake and baseline 25(OH)D concentrations. In addition, changes in other factors over time

Table 4. Concordance of classification of clinical categories of plasma 25-hydroxyvitamin D [25(OH)D] concentrations at follow-up (2002–2005) based on clinical categories at baseline (1997–2000) among 672 participants in the Osteoporosis and Periodontal Disease (OsteoPerio) Study

	Follow-up: At risk for deficiency (<30 nmol/L)	Follow-up: At risk for inadequacy (≥ 30 –<50 nmol/L)	Follow-up: Adequate (≥ 50 –<75 nmol/L)	Follow-up: Adequate (≥ 75 nmol/L)
Baseline: At risk for deficiency (<30 nmol/L)	14 (24.1%)	22 (37.9%)	20 (34.5%)	2 (3.5%)
Baseline: At risk for inadequacy (≥ 30 –<50 nmol/L)	6 (3.8%)	52 (33.1%)	80 (51.0%)	19 (12.1%)
Baseline: Adequate (≥ 50 –<75 nmol/L)	1 (0.3%)	30 (9.8%)	176 (57.7%)	98 (32.1%)
Baseline: Adequate (≥ 75 nmol/L)	1 (0.7%)	5 (3.3%)	41 (27.0%)	106 (69.7%)

NOTE: N and row percent presented.

such as sun exposure practices or percent body fat may also influence 25(OH)D status. To what extent certain participant characteristics and behaviors can explain change in 25(OH)D between baseline and follow-up was not the primary focus of this study but remains to be better understood. Previous work in WHI participants (20) showed that only 21% of the variation in 25(OH)D concentrations could be explained by the factors of season, vitamin D intake, waist circumference, recreational physical activity, race-ethnicity, regional solar irradiance, and age, with age explaining the least amount of variation among all factors. It seems unlikely that assay drift could explain our results as blind duplicates run consistently throughout the 4 months of 25(OH)D assessment had a CV of 4.9%. Explication of factors explaining change in vitamin D status over time and potential approaches to limit or correct their influence on longitudinal vitamin D status deserves further study.

This study has a number of strengths and limitations. One strength is the large sample size of our study. This is the largest study ($n = 672$) to date assessing intraindividual 25(OH)D variability in postmenopausal women. This study helps to interpret and analyze past and future epidemiologic studies of 25(OH)D and disease, particularly studies in postmenopausal women. Intraindividual variability in 25(OH)D, when used as an exposure for disease occurrence, likely would result in an attenuated estimates of association (e.g., relative risk; ref. 21). However, it is beyond the scope of this study to determine the nature and magnitude of the potential bias.

Second, the same laboratory and assay, with high quality control measures, was used to determine both baseline and follow-up plasma 25(OH)D concentrations over the same 4-month period. Measuring samples over a continuous 4-month period may minimize laboratory drifts that may occur if samples were measured 5 years apart. Third, blood samples were taken in the majority (66%) of participants in the same season at both time points. In addition, all women in our study were from the same latitude, which helped control, in part, for confounding from sun exposure.

Both a strength and a limitation of this study is the time between 25(OH)D measurements. Although 5 years is a significant amount of time that allows for 25(OH)D concentrations to fluctuate, it is only a small portion of an individual's life. Vitamin D status may fluctuate more over longer periods of time. Therefore, studies with repeat measures of vitamin D over longer time periods are warranted.

Another limitation is that our study results may only be applicable to Caucasian women living in Northern latitudes who use vitamin D supplements. Our study participants were all from the Buffalo, NY area, and the majority were consistent supplement users of vitamin D over time (71.9% at baseline and 88.7% at follow-up). Population data from the National Health and Nutrition Examination Survey (NHANES; ref. 22) showed that 49.7% of women 60 years and older used vitamin D

supplements from 1999–2002 and this number increased to 56.3% from 2003–2006. Although the women in this study have a higher prevalence of supplement use, both NHANES and the OsteoPerio study showed that older women were increasing their vitamin D supplement use over comparable time periods. The higher level of supplement use, in addition to the primarily Caucasian sample limits generalizability of study results. Inferences about intraindividual variability over time in other racial/ethnic groups should be made with caution.

On the basis of these study findings, we conclude that using a one-time assessment of 25(OH)D concentrations moderately reflects vitamin D status of individuals over an approximate 5-year period among individuals living at a similar latitude. Reliability of repeat measures seems to be moderately influenced by vitamin D supplement use and season of blood draw. Additional studies are warranted to (i) capture 25(OH)D trends using more frequent serial measurements of blood 25(OH)D concentrations and over longer periods of time, (ii) to better understand the ranking of individuals when 25(OH)D measures are taken in extreme seasons, and (iii) to better understand the reliability of measures in racially/ethnically diverse groups.

Disclosure of Potential Conflicts of Interest

A.E. Millen is a Co-investigator on a vitamin D related grant funded by the Mushroom Council (#10008). R.L. Horst is the Owner/Director of Heartland Assay, LLC. A.E. Millen had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All other authors have no disclosures or conflicts of interest.

Authors' Contributions

Conception and design: J.E. Meng, J. Wactawski-Wende, M.J. LaMonte, A.E. Millen

Development of methodology: J.E. Meng, J. Wactawski-Wende, A.E. Millen

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J. Wactawski-Wende, A.E. Millen

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.E. Meng, K.M. Hovey, C.A. Andrews, M.J. LaMonte, R.L. Horst, A.E. Millen

Writing, review, and/or revision of the manuscript: J.E. Meng, K.M. Hovey, J. Wactawski-Wende, C.A. Andrews, M.J. LaMonte, R.J. Genco, A.E. Millen

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): K.M. Hovey

Study supervision: R.J. Genco, A.E. Millen

Acknowledgments

The authors thank the women who generously contributed their time to participate in the OsteoPerio Study.

Grant Support

This research is supported by NIH grants 1R01DE13505 (awarded to J. Wactawski-Wende), 1R21DE020918 (awarded to A.E. Millen) from the National Institute of Dental and Craniofacial Research (NIDCR), and a grant awarded to J. Wactawski-Wende from the Department of Defense (DAMD179616319).

The WHI Program is supported by Contracts from the National Heart, Lung and Blood Institute, NIH (N01WH32122). The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 11, 2012; revised April 2, 2012; accepted April 4, 2012; published OnlineFirst April 20, 2012.

References

1. IOM (Institute of Medicine). Dietary reference intakes for calcium and vitamin D. Washington DC: The National Academy Press; 2011.
2. Zerwekh JE. Blood biomarkers of vitamin D status. *Am J Clin Nutr* 2008;87:1087S–91S.
3. Barragry JM, France MW, Corless D, Gupta SP, Switala S, Boucher BJ, et al. Intestinal cholecalciferol absorption in the elderly and in younger adults. *Clin Sci Mol Med* 1978;55:213–20.
4. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. *Cancer Causes Control* 2004;15:255–65.
5. Rejnmark L, Lauridsen AL, Brot C, Vestergaard P, Heickendorff L, Nexø E, et al. Vitamin D and its binding protein Gc: long-term variability in peri- and postmenopausal women with and without hormone replacement therapy. *Scand J Clin Lab Invest* 2006;66:227–38.
6. Hofmann JN, Yu K, Horst RL, Hayes RB, Purdue MP. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Cancer Epidemiol Biomarkers Prev* 2010;19:927–31.
7. Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G. Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. *Am J Epidemiol* 2010;171:903–8.
8. Kotsopoulos J, Tworoger SS, Campos H, Chung FL, Clevenger CV, Franke AA, et al. Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies. *Cancer Epidemiol Biomarkers Prev* 2010;19:938–46.
9. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, et al. The Women's Health Initiative recruitment methods and results. *Ann Epidemiol* 2003;13:S18–77.
10. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. *Ann Epidemiol* 2003;13:S107–21.
11. Wactawski-Wende J, Hausmann E, Hovey K, Trevisan M, Grossi S, Genco RJ. The association between osteoporosis and alveolar crestal height in postmenopausal women. *J Periodontol* 2005;76:2116–24.
12. Bole C, Wactawski-Wende J, Hovey KM, Genco RJ, Hausmann E. Clinical and community risk models of incident tooth loss in postmenopausal women from the Buffalo Osteo Perio Study. *Community Dent Oral Epidemiol* 2010;38:487–97.
13. Meyer AM, Evenson KR, Morimoto L, Siscovick D, White E. Test-retest reliability of the Women's Health Initiative physical activity questionnaire. *Med Sci Sports Exerc* 2009;41:530–8.
14. Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. *Ann Epidemiol* 1999;9:178–87.
15. Dawson-Hughes B, Harris S. Regional changes in body composition by time of year in healthy postmenopausal women. *Am J Clin Nutr* 1992;56:307–13.
16. Szklo M, Nieto FJ. Quality assurance and control. In: *Epidemiology: Beyond the basics*. 2nd ed. Sudbury, MA: Jones and Bartlett Publishers, LLC; 2007. p. 297–347.
17. How should I calculate a within-subject coefficient of variation? [cited 14 February 2012]. Available from: <http://www-users.york.ac.uk/~mb55/meas/cv.htm>
18. Armstrong BK, White E, Saracci R. Principles of exposure measurement in epidemiology. Oxford, United Kingdom: Oxford University Press; 1994.
19. Nakamura K, Nashimoto M, Yamamoto M. Summer/winter differences in the serum 25-hydroxyvitamin D3 and parathyroid hormone levels of Japanese women. *Int J Biometeorol* 2000;44:186–9.
20. Millen AE, Wactawski-Wende J, Pettinger M, Melamed ML, Tyllavsky FA, Liu S, et al. Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: the Women's Health Initiative Calcium plus Vitamin D Clinical Trial. *Am J Clin Nutr* 2010;91:1324–35.
21. Rosner B, Spiegelman D, Willett WC. Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. *Am J Epidemiol* 1992;136:1400–13.
22. Gahche J, Bailey R, Burt V, Hughes J, Yetley E, Dwyer J, et al. Dietary supplement use among U.S. adults has increased since NHANES III (1988–1994). NCHS data brief, no 61. Hyattsville, MD: National Center for Health Statistics; 2011.